<?xml version='1.0' encoding='UTF-8'?>
<search_results><query id="7147">breast cancer review</query><engine status="OK" timestamp="2014-04-21 01:19:51" name="The Street" id="FW14-e108"/><snippets><snippet id="FW14-e108-7147-01"><link cache="FW14-topics-docs/e108/7147_01.html" timestamp="2014-04-21 01:19:51">http://www.thestreet.com/story/11950405/1/wall-street-realizes-myriad-genetics-monopoly-on-breast-cancer-risk-tests-is-done.html</link><title>Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done</title><description>Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done

By Adam Feuerstein 07:43 AM EDT 06/14/13

Analyst downgrade Myriad following a Supreme Court ruling invalidating patents on human genese.

http://www.thestreet.com/story/11950405/1/wall-street-realizes-myriad-genetics-monopoly-on-breast-cancer-risk-tests-is-done.html</description><thumb cache="FW14-topics-docs/e108/7147_01_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/rx/pills10_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-02"><link cache="FW14-topics-docs/e108/7147_02.html" timestamp="2014-04-21 01:21:41">http://www.thestreet.com/story/12171303/1/big-pharma-stocks-year-in-review.html</link><title>Big Pharma Stocks: Year in Review</title><description>Big Pharma Stocks: Year in Review

By Richard Saintvilus 06:00 AM EST 12/24/13

Expect drug stocks to make new highs in 2014. But be selective.

http://www.thestreet.com/story/12171303/1/big-pharma-stocks-year-in-review.html</description><thumb cache="FW14-topics-docs/e108/7147_02_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/101612_biotech10_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-03"><link cache="FW14-topics-docs/e108/7147_03.html" timestamp="2014-04-21 01:24:15">http://www.thestreet.com/story/11538073/1/asco-12-abstract-dump-cancer-stocks-in-focus.html</link><title>ASCO '12 Abstract Dump: Cancer Stocks in Focus</title><description>ASCO '12 Abstract Dump: Cancer Stocks in Focus

By Adam Feuerstein 06:00 PM EDT 05/16/12

Array Biopharma, Exelixis, Aveo and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

http://www.thestreet.com/story/11538073/1/asco-12-abstract-dump-cancer-stocks-in-focus.html</description><thumb cache="FW14-topics-docs/e108/7147_03_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/101612_biotech3_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-04"><link cache="FW14-topics-docs/e108/7147_04.html" timestamp="2014-04-21 01:26:19">http://www.thestreet.com/story/11526558/1/fdas-review-of-arena-pharmas-obesity-drug-sunnier-than-expected.html</link><title>FDA's Review of Arena Pharma's Obesity Drug Sunnier Than Expected</title><description>FDA's Review of Arena Pharma's Obesity Drug Sunnier Than Expected

By Adam Feuerstein 12:10 PM EDT 05/08/12

FDA experts will vote Thursday on whether to recommend approval of Arena's lorcaserin for weight loss.

http://www.thestreet.com/story/11526558/1/fdas-review-of-arena-pharmas-obesity-drug-sunnier-than-expected.html</description><thumb cache="FW14-topics-docs/e108/7147_04_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/101612_drugs2_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-05"><link cache="FW14-topics-docs/e108/7147_05.html" timestamp="2014-04-21 01:28:55">http://www.thestreet.com/story/12088634/1/odds-favor-endocyte-receiving-european-approval-for-ovarian-cancer-drug.html</link><title>Odds Favor Endocyte Receiving European Approval For Ovarian Cancer Drug</title><description>Odds Favor Endocyte Receiving European Approval For Ovarian Cancer Drug

By David Sobek 11:26 AM EDT 10/30/13

Vintafolide benefits ovarian cancer patients with no current treatment options, phase II data shows.

http://www.thestreet.com/story/12088634/1/odds-favor-endocyte-receiving-european-approval-for-ovarian-cancer-drug.html</description><thumb cache="FW14-topics-docs/e108/7147_05_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/101612_drugs1_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-06"><link cache="FW14-topics-docs/e108/7147_06.html" timestamp="2014-04-21 01:31:29">http://www.thestreet.com/story/11539763/1/asco-12-abstract-dump-cancer-stocks-in-focus-update.html</link><title>ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)</title><description>ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

By Adam Feuerstein 06:19 AM EDT 05/17/12

Array Biopharma, Exelixis,Onyx Pharma and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

http://www.thestreet.com/story/11539763/1/asco-12-abstract-dump-cancer-stocks-in-focus-update.html</description><thumb cache="FW14-topics-docs/e108/7147_06_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/101612_biotech2_139x90.jpg</thumb></snippet><snippet id="FW14-e108-7147-07"><link cache="FW14-topics-docs/e108/7147_07.html" timestamp="2014-04-21 01:33:36">http://www.thestreet.com/story/11912111/1/why-aveos-tivozanib-should-win-fda-approval.html</link><title>Why Aveo's Tivozanib Should Win FDA Approval</title><description>Why Aveo's Tivozanib Should Win FDA Approval

By Covestor.com 06:06 AM EDT 05/02/13

Aveo's Tivozanib kidney cancer drug will get the nod from regulators.

http://www.thestreet.com/story/11912111/1/why-aveos-tivozanib-should-win-fda-approval.html</description><thumb cache="FW14-topics-docs/e108/7147_07_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/market_story_6_thumb.jpg</thumb></snippet><snippet id="FW14-e108-7147-08"><link cache="FW14-topics-docs/e108/7147_08.html" timestamp="2014-04-21 01:37:27">http://www.thestreet.com/story/11566916/1/asco-12-stocks-winners-and-losers.html</link><title>ASCO '12 Stocks: Winners and Losers</title><description>ASCO '12 Stocks: Winners and Losers

By Adam Feuerstein 06:00 AM EDT 06/04/12

Snap judgments in biotech and drug stocks after a weekend spent at the ASCO cancer meeting.

http://www.thestreet.com/story/11566916/1/asco-12-stocks-winners-and-losers.html</description><thumb cache="FW14-topics-docs/e108/7147_08_thumb.jpg">http://i.thestreet.com/files/tsc/v2008/photos/all-pics/rx/pills-139x90-19.jpg</thumb></snippet><snippet id="FW14-e108-7147-09"><link cache="FW14-topics-docs/e108/7147_09.html" timestamp="2014-04-21 01:39:30">http://www.thestreet.com/story/10288131/1/genentech-bids-for-new-avastin-use.html</link><title>Genentech Bids for New Avastin Use</title><description>Genentech Bids for New Avastin Use

By Althea Chang 12:45 PM EDT 05/25/06

The company wants the FDA to approve the drug for treating breast cancer.

http://www.thestreet.com/story/10288131/1/genentech-bids-for-new-avastin-use.html</description></snippet><snippet id="FW14-e108-7147-10"><link cache="FW14-topics-docs/e108/7147_10.html" timestamp="2014-04-21 01:40:57">http://www.thestreet.com/story/10274152/1/wyeth-stops-breast-cancer-trial.html</link><title>Wyeth Stops Breast Cancer Trial</title><description>Wyeth Stops Breast Cancer Trial

By Althea Chang 05:45 PM EST 03/16/06

The study involved the experimental drug temsirolimus and Femara.

http://www.thestreet.com/story/10274152/1/wyeth-stops-breast-cancer-trial.html</description></snippet></snippets></search_results>